EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Hypermethylation of OPRM1: Deregulation of the Endogenous Opioid Pathway in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome and Fibromyalgia

Arne Wyns iD, Jolien Hendrix iD, Jente Van Campenhout iD, Yanthe Buntinx iD, Huan-Yu Xiong iD, Elke De Bruyne, Lode Godderis iD, Jo Nijs iD, David Rice, Daniel Chiang, Andrea Polli iD

International Journal of Molecular Sciences · 2026

DOI: 10.3390/ijms27020826 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2026. Verfasst von Arne Wyns und 10 weiteren Autor:innen. Beteiligte Einrichtung: Pain in Motion (PiM) International Research Group, Department of Physiotherapy, Human Physiology and Anatomy, Faculty of Rehabilitation Sciences & Ph…. Hauptthemen laut MEDLINE: Receptors, Opioid, mu, Fatigue Syndrome, Chronic, DNA Methylation, Fibromyalgia. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 72 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: ME Research UK, European College for Lymphatic Therapy in the Netherlands.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) and fibromyalgia (FM) are debilitating disorders with overlapping symptoms such as chronic pain and fatigue. Dysregulation of the endogenous opioid system, particularly µ-opioid receptor function, may contribute to their pathophysiology. This study examined whether epigenetic modifications, specifically µ-opioid receptor 1 gene (OPRM1) promoter methylation, play a role in this dysfunction. Using a repeated-measures design, 28 ME/CFS/FM patients and 26 matched healthy controls visited the hospital twice within four days. Assessments included blood sampling for epigenetic analysis, a clinical questionnaire battery, and quantitative sensory testing (QST). Global DNA (hydroxy)methylation was quantified via liquid chromatography–tandem mass spectrometry, and targeted pyrosequencing was performed on promoter regions of OPRM1, COMT, and BDNF. ME/CFS/FM patients reported significantly worse symptom outcomes. No differences in global (hydroxy)methylation were found. Patients showed significantly higher OPRM1 promoter methylation, which remained after adjusting for symptom severity and QST findings. Across timepoints, OPRM1 methylation consistently correlated with BDNF Promoter I and Exon III methylation. This is, to the best of our knowledge, the first study examining OPRM1 methylation in ME/CFS/FM. Increased OPRM1 methylation in patients, independent of symptoms or pain sensitivity measures, supports the hypothesis of dysregulated opioidergic signaling in these conditions.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Receptors, Opioid, muFatigue Syndrome, ChronicDNA MethylationFibromyalgiaHumansPromoter Regions, GeneticFemaleMiddle AgedAdultEpigenesis, GeneticMaleBrain-Derived Neurotrophic FactorCatechol O-Methyltransferase

Stichwörter der Autor:innen

OPRM1bisulfite conversiondescending modulationepigeneticsfibromyalgiamyalgic encephalomyelitis/chronic fatigue syndromeopioids

Substanzen

Receptors, Opioid, muOPRM1 protein, humanBrain-Derived Neurotrophic FactorCatechol O-Methyltransferase

Autor:innen und Institutionen

  • Pain in Motion (PiM) International Research Group, Department of Physiotherapy, Human Physiology and Anatomy, Faculty of Rehabilitation Sciences & Physiotherapy, Vrije Universiteit Brussel, Laarbeeklaan 103, 1090 Jette,…
  • Department of Public Health and Primary Care, Centre for Environment & Health, KU Leuven, Kapucijnenvoer 35, 3000 Leuven, Belgium.
  • Flanders Research Foundation-FWO, 1000 Brussels, Belgium.
  • Translational Oncology Research Center (TORC), Team Hematology and Immunology (HEIM), Vrije Universiteit Brussel, 1090 Jette, Belgium.
  • External Service for Prevention and Protection at Work, IDEWE, 3001 Heverlee, Belgium.
  • Department of Physical Medicine and Physiotherapy, University Hospital Brussels, 1000 Jette, Belgium.

ORCID-Profile: Arne Wyns, Jolien Hendrix, Jente Van Campenhout, Yanthe Buntinx, Huan-Yu Xiong, Lode Godderis, Jo Nijs, Andrea Polli

Förderung

  • ME Research UK
  • European College for Lymphatic Therapy in the Netherlands

Zitieren

APA

Wyns, A., Hendrix, J., Van Campenhout, J., Buntinx, Y., Xiong, H. Y., De Bruyne, E., Godderis, L., Nijs, J., Rice, D., Chiang, D., & Polli, A. (2026). Hypermethylation of OPRM1: Deregulation of the Endogenous Opioid Pathway in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome and Fibromyalgia. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms27020826

Vancouver

Wyns A, Hendrix J, Van Campenhout J, Buntinx Y, Xiong HY, De Bruyne E, et al. Hypermethylation of OPRM1: Deregulation of the Endogenous Opioid Pathway in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome and Fibromyalgia. International Journal of Molecular Sciences. 2026. doi:10.3390/ijms27020826

BibTeX
@article{Wyns2026,
  author = {Wyns, Arne and Hendrix, Jolien and Van Campenhout, Jente and Buntinx, Yanthe and Xiong, Huan-Yu and De Bruyne, Elke and Godderis, Lode and Nijs, Jo and Rice, David and Chiang, Daniel and Polli, Andrea},
  title = {Hypermethylation of OPRM1: Deregulation of the Endogenous Opioid Pathway in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome and Fibromyalgia},
  journal = {International Journal of Molecular Sciences},
  year = {2026},
  doi = {10.3390/ijms27020826}
}
Kostenlos starten →